Potent and selective CDK4/6 inhibitor (IC50 = 2 nM and 10 nM respectively). Induces G1 cell cycle arrest in colo-205 colorectal cells, MDA-MB-361 breast cancer cells, and MV4-11 AML cells; also active in several human tumor xenograft models. Displays efficacy in patients with various solid...
Know who made it. See the evidence. Buy through one marketplace.
Potent and selective CDK4/6 inhibitor (IC50 = 2 nM and 10 nM respectively). Induces G1 cell cycle arrest in colo-205 colorectal cells, MDA-MB-361 breast cancer cells, and MV4-11 AML cells; also active in several human tumor xenograft models. Displays efficacy in patients with various solid tumors including breast cancer, non-small cell lung cancer, glioblastoma, melanoma, colorectal cancer, and hormone receptor-positive breast cancer. Abemaciclib induced a T cell inflamed tumor microenvironment and enhanced the efficacy of PD-L1 checkpoint blockade in MCF-7 breast cancer cells. FDA approved for the treatment of advanced breast cancers
This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
